Compositions and methods for the treatment of neurological disorders whereby vectors contain codon-optimized nucleic acids for expression in humans, encoding a human dopamine receptor D1 protein, a human 5-Hydroxytryptamine receptor 4 protein, and a human G-protein coupled receptor 139).